{"id":14605,"date":"2021-04-30T08:33:40","date_gmt":"2021-04-30T06:33:40","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=14605"},"modified":"2024-12-11T13:12:53","modified_gmt":"2024-12-11T12:12:53","slug":"inhibition-de-bcl-2-dans-le-lymphome-b-diffus-a-grandes-cellules","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/inhibition-de-bcl-2-dans-le-lymphome-b-diffus-a-grandes-cellules\/","title":{"rendered":"Inhibition de Bcl-2 dans le lymphome B diffus \u00e0 grandes cellules"},"content":{"rendered":"<div class=\"fusion-fullwidth fullwidth-box fusion-builder-row-1 fusion-flex-container nonhundred-percent-fullwidth non-hundred-percent-height-scrolling\" style=\"--awb-border-radius-top-left:0px;--awb-border-radius-top-right:0px;--awb-border-radius-bottom-right:0px;--awb-border-radius-bottom-left:0px;--awb-flex-wrap:wrap;\" ><div class=\"fusion-builder-row fusion-row fusion-flex-align-items-flex-start fusion-flex-content-wrap\" style=\"max-width:calc( 1240px + 0px );margin-left: calc(-0px \/ 2 );margin-right: calc(-0px \/ 2 );\"><div class=\"fusion-layout-column fusion_builder_column fusion-builder-column-0 fusion_builder_column_1_1 1_1 fusion-flex-column\" style=\"--awb-bg-size:cover;--awb-width-large:100%;--awb-margin-top-large:0px;--awb-spacing-right-large:0px;--awb-margin-bottom-large:0px;--awb-spacing-left-large:0px;--awb-width-medium:100%;--awb-spacing-right-medium:0px;--awb-spacing-left-medium:0px;--awb-width-small:100%;--awb-spacing-right-small:0px;--awb-spacing-left-small:0px;\"><div class=\"fusion-column-wrapper fusion-flex-justify-content-flex-start fusion-content-layout-column\"><div class=\"fusion-text fusion-text-1\"><div><span lang=\"EN-US\">R\u00e9f. : HematoStat.net ; 2(1) : R10<\/span><\/div>\n<div><\/div>\n<div><em><strong><span lang=\"EN-US\">phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma<\/span><\/strong><\/em><\/div>\n<div><\/div>\n<div>\n<div><i><span lang=\"EN-US\">Morschhauser, F. et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. <\/span>Blood 137, 600\u2013609 (2021).<\/i><\/div>\n<\/div>\n<div>\n<h3>R\u00e9sum\u00e9 :<\/h3>\n<p>Dans l\u2019essai de phase 2 CAVALLI, des patients adultes atteints de lymphomes B diffus \u00e0 grandes cellules (DLBCL) en premi\u00e8re ligne \u00e9taient inclus. Les patients recevaient 6 \u00e0 8 cycles de R-CHOP tous les 21 jours en association au v\u00e9n\u00e9toclax (VEN, inhibiteur de Bcl-2) \u00e0 la dose de 800 mg\/jour de J1 \u00e0 J10 (J4 \u00e0 J10 lors du cycle 1). Les effets secondaires \u00e9taient domin\u00e9s par la my\u00e9losuppression avec 31 % de neutrop\u00e9nies f\u00e9briles. La survie sans progression \u00e0 24 mois \u00e9tait de 79,6 %.<\/p>\n<h3>Dans nos pratiques :<\/h3>\n<p>Apr\u00e8s des r\u00e9sultats dans les lymphomes en rechute ou r\u00e9fractaire, le VEN poursuit son d\u00e9veloppement et s\u2019invite en 1<sup>re <\/sup>ligne. On observe ici que l\u2019ajout de VEN pourrait permettre d\u2019am\u00e9liorer le contr\u00f4le du lymphome, au prix d\u2019une toxicit\u00e9 accrue qui n\u00e9cessite une surveillance rapproch\u00e9e et des adaptations de dose. Cette strat\u00e9gie pourrait s\u2019av\u00e9rer payante en ciblant des patients de haut-risque et exprimant Bcl-2.<\/p>\n<h3><strong>Le regard du statisticien<\/strong><\/h3>\n<p>Cet essai de phase 2 a plusieurs points forts notamment un effectif important (211 patients) et une comparaison avec le bras R-CHOP d\u2019une autre \u00e9tude (GOYA\/BO21005), ce qui \u00e9videmment ne remplace pas un v\u00e9ritable essai de phase III mais donne de bons points de rep\u00e8re. Passer \u00e0 la phase suivante pour confirmer l\u2019int\u00e9r\u00eat de l\u2019association avec le v\u00e9n\u00e9toclax sera attendu.<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"","protected":false},"author":16,"featured_media":14593,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[36],"tags":[],"ppma_author":[456],"class_list":["post-14605","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-revue-de-presse","author-alexis-genthon"],"aioseo_notices":[],"authors":[{"term_id":456,"user_id":16,"is_guest":0,"slug":"alexis-genthon","display_name":"Alexis GENTHON","avatar_url":{"url":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2021-05-07-a-14.25.02.png","url2x":"https:\/\/www.hematostat.net\/wp-content\/uploads\/2023\/06\/Capture-decran-2021-05-07-a-14.25.02.png"},"first_name":"","last_name":"","user_url":"","description":"H\u00e9matologue.\r\nCorrespondance : H\u00f4pital Saint-Antoine \r\nService h\u00e9matologie clinique\r\n184 rue du Faubourg Saint-Antoine 75012 Paris."}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/14605","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=14605"}],"version-history":[{"count":1,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/14605\/revisions"}],"predecessor-version":[{"id":18177,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/14605\/revisions\/18177"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=14605"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=14605"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=14605"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=14605"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}